Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anticancer drug resistance: An update and perspective
Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang
Drug Resistance Updates (2021) Vol. 59, pp. 100796-100796
Open Access | Times Cited: 246

Showing 1-25 of 246 citing articles:

Nanomaterials in tumor immunotherapy: new strategies and challenges
Xudong Zhu, Shenglong Li
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 101
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance
Xu Guo, Congying Gao, Dong‐Hua Yang, et al.
Drug Resistance Updates (2023) Vol. 67, pp. 100937-100937
Closed Access | Times Cited: 99
The pyroptotic role of Caspase-3/GSDME signalling pathway among various cancer: A Review
Asif Ahmad Bhat, Riya Thapa, Obaid Afzal, et al.
International Journal of Biological Macromolecules (2023) Vol. 242, pp. 124832-124832
Closed Access | Times Cited: 93
The Role of Silver Nanoparticles in the Diagnosis and Treatment of Cancer: Are There Any Perspectives for the Future?
Peter Takáč, Radka Michalková, Martina Čižmáriková, et al.
Life (2023) Vol. 13, Iss. 2, pp. 466-466
Open Access | Times Cited: 85
Unveiling the mechanisms and challenges of cancer drug resistance
Sameer Ullah Khan, Kaneez Fatima, Shariqa Aisha, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 85
N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells
Zhihua Liu, Nanxin Zheng, Juan Li, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100886-100886
Closed Access | Times Cited: 76
Autophagy-driven regulation of cisplatin response in human cancers: Exploring molecular and cell death dynamics
Yang Yang, Lixia Liu, Yu Tian, et al.
Cancer Letters (2024) Vol. 587, pp. 216659-216659
Open Access | Times Cited: 70
Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents
Enrique Domínguez‐Álvarez, Bálint Rácz, Małgorzata Anna Marć, et al.
Drug Resistance Updates (2022) Vol. 63, pp. 100844-100844
Open Access | Times Cited: 69
Nano-drug delivery system targeting tumor microenvironment: A prospective strategy for melanoma treatment
Mengdan Xu, Shenglong Li
Cancer Letters (2023) Vol. 574, pp. 216397-216397
Open Access | Times Cited: 60
Application of artificial intelligence and machine learning in early detection of adverse drug reactions (ADRs) and drug-induced toxicity
Siyun Yang, Supratik Kar
Artificial Intelligence Chemistry (2023) Vol. 1, Iss. 2, pp. 100011-100011
Open Access | Times Cited: 46
A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy
Jiaying Zhang, Bo Chen, Chunyuan Gan, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 7605-7635
Open Access | Times Cited: 45
Application of artificial intelligence in diagnosis and treatment of colorectal cancer: A novel Prospect
Zugang Yin, Chenhui Yao, Limin Zhang, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 42
Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy
Kenneth K.W. To, Zoufang Huang, Hang Zhang, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101058-101058
Closed Access | Times Cited: 20
Designing a Mitochondria-Targeted Theranostic Cyclometalated Iridium(III) Complex: Overcoming Cisplatin Resistance and Inhibiting Tumor Metastasis through Necroptosis and Immune Response
Wenjuan Li, Ting Li, Ying Pan, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 5, pp. 3843-3859
Closed Access | Times Cited: 20
Revisiting luteolin: An updated review on its anticancer potential
Abdur Rauf, Polrat Wilairatana, Payal B. Joshi, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26701-e26701
Open Access | Times Cited: 17
Orthotopic and metastatic tumour models in preclinical cancer research
Stephen M. Stribbling, Callum Beach, Anderson J. Ryan
Pharmacology & Therapeutics (2024) Vol. 257, pp. 108631-108631
Open Access | Times Cited: 17
Molecular principles underlying aggressive cancers
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells
Cristina P. R. Xavier, Dimas Carolina Belisario, Rita Rebelo, et al.
Drug Resistance Updates (2022) Vol. 62, pp. 100833-100833
Open Access | Times Cited: 57
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma
Manfei Pi, Huixian Kuang, Chunyan Yue, et al.
Drug Resistance Updates (2022) Vol. 61, pp. 100822-100822
Closed Access | Times Cited: 56
Luteolin: a flavonoid with a multifaceted anticancer potential
Parteek Prasher, Mousmee Sharma, Sachin Kumar Singh, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 53
Biological and pharmacological roles of m6A modifications in cancer drug resistance
Zaoqu Liu, Haijiao Zou, Qin Dang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 52
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Ruth Nussinov, Mingzhen Zhang, Ryan Maloney, et al.
Journal of Molecular Biology (2022) Vol. 434, Iss. 17, pp. 167569-167569
Open Access | Times Cited: 44
Neurodevelopmental disorders, like cancer, are connected to impaired chromatin remodelers, PI3K/mTOR, and PAK1-regulated MAPK
Ruth Nussinov, Bengi Ruken Yavuz, M. Kaan Arici, et al.
Biophysical Reviews (2023) Vol. 15, Iss. 2, pp. 163-181
Open Access | Times Cited: 35
Triazole-fused pyrimidines in target-based anticancer drug discovery
Xing‐Jie Dai, Lei-Peng Xue, Shi‐Kun Ji, et al.
European Journal of Medicinal Chemistry (2023) Vol. 249, pp. 115101-115101
Closed Access | Times Cited: 31
Protein degradation: expanding the toolbox to restrain cancer drug resistance
Hui Ming, Bowen Li, Jingwen Jiang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top